Axillary staging of breast cancer and the sentinel node

Journal of Clinical Pathology

Volumn 53, Issue 10, 2000, Pages 733-741

  Cserni, G ^a  

^a BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

Author keywords

Axillary staging; Breast cancer; Sentinel lymph node

Indexed keywords

ARTICLE; BREAST CANCER; CANCER STAGING; CYTOLOGY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; INTRAOPERATIVE CARE; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; QUALITY CONTROL; SENTINEL LYMPH NODE BIOPSY;

EID: 0033770718     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.10.733     Document Type: Article

References (151)

1. 1 Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer 1978;41:1170-8.
2. 2 Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551-7.
3. 3 Henson DE, Fielding P, Grignon DJ, et al. College of American Pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Arch Pathol Lab Med 1995;119:1109-12.
4. 4 Turnbull AR, Chant ADB, Buchanan RB, et al. Treatment of early breast cancer. Lancet 1978:2:7-9.
5. 5 Davies GC, Millis RR, Hayward JL. Assessment of axillary lymph node status. Ann Surg 1980;192:148-51.
6. 6 Fisher B, Wolmark N, Bauer M, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-72.
7. 7 Danforth DN, Jr, Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for stage I II carcinoma of the breast. J Clin Oncol 1986;4:655-62.
8. 8 Sacre RA. Clinical evaluation of axillary lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol 1986;12:169-73.
9. 9 Kinne DW. Controversies in primary breast cancer management. Am J Surg 1993;166:502-8.
10. 10 McLean RG, Ege GN. Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients. J Nucl Med 1986;27:1116-24.
11. 11 Uren RF, Howman-Giles RB, Thompson JF, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995;36:1775-80.
12. 12 March DE, Weschler RJ, Kurtz AB, et al. CT-pathologic correlation of axillary lymph nodes in breast carcinoma. J Comput Assist Tomogr 1991;15:440-4.
13. 13 Mussurakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. Radiology 1997; 203:317-21.
14. 14 Crowe JP, Adler MD, Shenk RR, et al. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1:132-40.
15. 15 Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2 deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204-9.
16. 16 Tate JJT, Lewis V, Archer T, et al. Ultrasound detection of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 1989;15:139-42.
17. 17 De Freitas R Jr, Costa MV, Schneider SV, et al. Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 1991;17:240-4.
18. 18 Vassallo P, Wernecke K, Roos N, et al. Differentiation between benign from malignant superficial lymphadenopathy: the role of high resolution US. Radiology 1992;183:215-20.
19. 19 Noguchi M, Katev N, Miyazaki I. Diagnosis of axillary metastases in patients with breast cancer. Breast Cancer Res Treat 1996;40:283-93.
20. 20 Mathiesen O, Carl J, Bonderup O, et al. Axillary sampling and the risk of erroneous staging of breast cancer. Acta Oncol 1990;29:721-5.
21. 21 Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992; 69:2496-501.
22. 22 Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 1992;28A:1415-18.
23. 23 Wilking N, Rutquist LE, Carstensen J, et al. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol 1992; 31:29-35.
24. 24 Senofsky GM, Moffat FL, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991;126:1336-42.
25. 25 Mofatt FL Jr, Senofsky GM, Davis K, et al. Axillary node dissection for early breast cancer: some is good, but all is better. J Surg Oncol 1992;51:8-13.
26. 26 Davidson T. Why I favour axillary node clearance in the management of breast cancer. Eur J Surg Oncol 1995;21:5-7.
27. 27 Cady B. Total mastectomy and partial axillary dissection. Surg Clin North Am 1973;53:313-18.
28. 28 Boova RS, Bonanni R, Rosato FE. Patterns of axillary nodal involvement in breast cancer. Ann Surg 1982;196:642-4.
29. 29 Kjaergaard J, Blichert-Toft M, Andersen JA, et al. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg 1985;72: 365-7.
30. 30 Forrest APM, Roberts MM, Cant E, et al. Simple mastectomy and pectoral node biopsy. Br J Surg 1976;63: 569-75.
31. 31 Steele RJC, Forrest APM, Gibson T, et al. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br J Surg 1985;72:368-9.
32. 32 Blichert-Toft M, Smola MG, Cataliotti L, et al. Principles and guidelines for surgeons -management of symptomatic breast cancer. On behalf of the European Society of Surgical Oncology. Eur J Surg Oncol 1997;23:101-9.
33. 33 Greenall MJ. Why I favour axillary node sampling in the management of breast cancer. Eur J Surg Oncol 1995;21:2-5.
34. 34 Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970;131:79-88.
35. 35 Reynolds JV, Mercer P, McDermot EWM, et al. Audit of complete axillary dissection in early breast cancer. Eur J Cancer 1994;30A:148-9.
36. 36 Cserni G. How to improve low lymph node recovery rates from axillary clearance specimens of breast cancer? A short-term audit. J Clin Pathol 1998;51:846-9.
37. 37 Morrow M, Evans J, Rosen PP, et al. Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma? Cancer 1984;53:1329-32.
38. 38 Kingsley WB, Peters GN, Cheek JH. What constitutes adequate study of axillary lymph nodes in breast cancer? Ann Surg 1985;201:311-14.
39. 39 National Coordinating Group for Breast Screening Pathology. Pathology reporting in breast cancer screening, 2nd ed. Sheffield: NHSBSP Publications, 1997.
40. 40 Cserni G. The reliability of sampling 3 to 6 nodes for staging breast cancer. J Clin Pathol 1999;52:681-3.
41. 41 Pickren JW. Significance of occult metastases - a study of breast cancer. Cancer 1961;14:1266-71.
42. 42 Fisher ER, Swamidoss S, Lee CH, et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
43. 43 Wells CA, Heryet A, Brochier J, et al. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50:193-7.
44. 44 Trojani M, Mascarel ID, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
45. 45 Apostolikas N, Petrai C, Agnantis NJ. The reliability of histologically negative axillary lymph nodes in breast cancer. Pathol Res Pract 1989;184:35-8.
46. 46 International Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
47. 47 Springall RJ, Rytina ERC, Millis RR. Incidence and significance of micrometastases in axillary lymph nodes detected by immunohistochemical techniques [abstract]. J Pathol 1990;160:174A.
48. 48 Galea M, Athanassiou E, Bell J, et al. Occult regional lymph node metastases from breast carcinoma: immunohistochemical detection with antibodies CAM 5.2 and NCRC-11. J Pathol 1991;165:221-7.
49. 49 Fisher ER, Palekar A, Rockette H, et al. Pathological findings from the national surgical adjuvant breast project (protocol no. 4) V. Significance of axillary nodal micro and macro metastases. Cancer 1978;42:2032-8.
50. 50 Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 1999;354:896-900.
51. 51 Rosen PP, Saigo P, Weathers E, et al. Axillary micro-and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981;194:585-91.
52. 52 Dowlatshahi K, Fan M, Snider HC, et al. Lymph node micrometastases from breast carcinoma. Reviewing the dilemma. Cancer 1997;80:1188-97.
53. 53 Kissin MW, Querci della Rovere G, Easton D, et al. Risk of lymphoedema following the treatment of breast cancer. Br J Surg 1986;73:580-4.
54. 54 Larson D, Weinsteín M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1575-82.
55. 55 Ivens D, Hoe A, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66: 136-8.
56. 56 Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996;131:301-8.
57. 57 Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66.
58. 58 Morton DL, Wen DR, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
59. 59 Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-40.
60. 60 Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8.
61. 61 Bilchik AJ, Giuliano A, Essner R, et al. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 1998;4: 351-8.
62. 62 Beechey-Newman N. Sentinel node biopsy: a revolution in the surgical management of breast cancer? Cancer Treat Rev 1998;24:185-203.
63. 63 Miltenburg DM, Miller C, Karamlou TB, et al. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138-42.
64. 64 Hsueh EC, Turner RR, Glass EC, et al. Sentinel node biopsy in breast cancer. J Am Coll Surg 1999;189:207-13.
65. 65 Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15: 2345-50.
66. 66 Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer. A multicenter validation study. N Engl J Med 1998;339:941-6.
67. 67 Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999;91:368-73.
68. 68 Bass SS, Cox CE, Ku NN, et al. The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg 1999;189: 183-94.
69. 69 Cserni G. Misidentification of an axillary sentinel lymph node due to anthracosis. Eur J Surg Oncol 1998;24:168.
70. 70 Miner TJ, Shriver CD, Flicek PR, et al. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node. Ann Surg Oncol 1999; 6:75-82.
71. 71 Glass EC, Basinski JE, Krasne DL, et al. Radiation safety considerations for sentinel node techniques. Ann Surg Oncol 1999;6:10-11.
72. 72 Waddington WA, Keshtgar MRS, Saunders C, et al. Radiation safety issues for sentinel node biopsy in breast cancer [abstract]. Eur J Nucl Med 1999;26(suppl):S61.
73. 73 Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
74. 74 Roumen RM, Valkenburg JG, Geuskens LM. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur J Surg Oncol 1997; 23:495-502.
75. 75 Dale PS, Williams JT. Axillary staging utilizing selective sentinel lymphadenectomy for patients with invasive breast carcinoma. Am Surgeon 1998;64:28-32.
76. 76 Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 1998;5:126-30.
77. 77 Reuhl T, Kaisers H, Markwardt J, et al. Axillaausraumung bei klinisch nodal-negativen Mammakarzinom. Kann die Indikation durch "sentinel node" - Nachweis individualisiert werden? Dtsch Med Wochenschr 1998;123:583-7.
78. 78 O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423-7.
79. 79 Koller M, Barsuk D, Zippel D, et al. Sentinel lymph node involvement - a predictor for axillary node status with breast cancer - has the time come? Eur J Surg Oncol 1998; 24:166-8.
80. 80 Krag DN, Ashikaga T, Harlow SP, et al. Development of sentinel node targeting technique in breast cancer patients. The Breast Journal 1998;4:67-74.
81. 81 Flett MM, Going JJ, Stanton FD, et al. Sentinel node localization in patients with breast cancer. Br J Surg 1998;85: 991-3.
82. 82 Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;180:700-4.
83. 83 Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
84. 84 Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997;3:336-40.
85. 85 Pijpers R, Meijer S, Hoekstra OS, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 1997;38:366-8.
86. 86 Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-83.
87. 87 Jannink I, Fan M, Nagy S, et al. Serial sectioning of sentinel nodes in patients with breast cancer: a pilot study. Ann Surg Oncol 1998;5:310-14.
88. 88 Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999;85:1098-103.
89. 89 Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma. A preliminary study. Cancer 1999;86: 990-6.
90. 90 Cserni G. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol 1999;52:922-4.
91. 91 American Joint Committee on Cancer. Breast. In: Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997:171-80.
92. 92 Turner RR, Ollila DW, Krasne DL, et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-6.
93. 93 Koopal SA, Doting E, de Vries J, et al. The value of immunohistochemistry of sentinel and non sentinel nodes in primary breast cancer [abstract]. Eur J Nucl Med 1999; 26(suppl):S75.
94. 94 Kelley SW, Komorowski RA, Dayer AM. Axillary sentinel lymph nodes examination in breast carcinoma. Arch Pathol Lab Med 1999;123:533-5.
95. 95 Pendas S, Dauway E, Cox CE, et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999;65:500-6.
96. 96 Torrenga H, Rahusen FD, Borgstein PJ, et al. Immunohistochemical detection of lymph-node metastases. Lancet 2000;355:144.
97. 97 Cox CE. Clinical relevance of serial sectioning of sentinel nodes and the detection of micrometastatic nodal disease in breast cancer. Ann Surg Oncol 1998;5:297-8.
98. 98 Bland KI. Microstaging of sentinel lymph nodes. Ann Surg Oncol 1999;6:15-16.
99. 99 Ollila DW, Brennan MB, Giuliano AE. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer. Arch Surg 1998;133:647-51.
100. 100 McIntosh SA, Going JJ, Soukop M, et al. Therapeutic implications of the sentinel lymph node in breast cancer. Lancet 1999;354:570.
101. 101 Meyer JS. Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. J Surg Oncol 1998;69:212-18.
102. 102 Allred DC, Elledge RM. Caution concerning micrometastatic breast carcinoma in sentinel lymph nodes. Cancer 1999;86:905-7.
103. 103 Anderson TJ. The challenge of sentinel lymph node biopsy. Histopathology 1999;35:82-4.
104. 104 Turner RR, Ollila DW, Stern S, et al. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 1999;23:263-7.
105. 105 Diest PJ van. Histopathological workup of sentinel lymph nodes: how much is enough? J Clin Pathol 1999;52:871-3.
106. 106 Cserni G. Mapping metastases in sentinel lymph nodes of breast cancer. Am J Clin Pathol 2000;113:351-4.
107. 107 Ku NNK. Pathologic examination of sentinel lymph nodes in breast cancer. Surg Oncol Clin North Am 1999;8:469-79.
108. 108 Ku NN, Ahmad N, Smith PV, et al. Intraoperative imprint cytology of sentinel lymph nodes in breast cancer [abstract]. Acta Cytol 1997;41:1606-7.
109. 109 Turner RR, Hansen NM, Stern SL, et al. Intraoperative examination of the sentinel lymph node for breast carcinoma staging. Am J Clin Pathol 1999;112:627-34.
110. 110 Ratanawichitrasin A, Biscotti CV, Levy L, et al. Touch imprint cytological analysis of sentinel lymph nodes for detecting axillary metastases in patients with breast cancer. Br J Surg 1999;86:1346-9.
111. 111 Richter T, Nahring J, Komminoth P, et al. Protocol for ultrarapid immunostaining of frozen sections. J Clin Pathol 1999;52:461-3.
112. 112 Viale G, Bosari S, Mazzarol G, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999;85:2433-8.
113. 113 Association of Directors of Anatomic and Surgical Pathology. Immediate management of mammographically detected breast lesions. Pathology Case Reviews 1996;1:3-4.
114. 114 Fechner RE. Practice parameter: frozen section examination of breast biopsies. Am J Clin Pathol 1995;103:6-7.
115. 115 Cavanese G, Gipponi M, Catturich A, et al. Sentinel lymph node mapping opens a new perspective in the surgical management of early-stage breast cancer: a combined approach with vital blue dye lymphatic mapping and radio-guided surgery. Semin Surg Oncol 1998;15:272-7.
116. 116 Schneebaum S, Stadler J, Cohen M, et al. Gamma probe-guided sentinel node biopsy - optimal timing for injection. Eur J Surg Oncol 1998;24:515-19.
117. 117 Diest PJ van, Torrenga H, Borgstein PJ, et al. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology 1999;35:14-18.
118. 118 Mayzler O, Goldstein J, Koretz M. Is frozen section examination of the sentinel lymph node a reliable predictor of histologic status [abstract]? Eur J Nucl Med 1999; 26(suppl):S56.
119. 119 Noguchi M, Bando E, Tsugawa K, et al. Staging efficacy of breast cancer with sentinel lymphadenectomy. Breast Cancer Res Treat 1999;57:221-9.
120. 120 Turner RR, Giuliano AE. Intraoperative pathologic examination of the sentinel lymph node. Ann Surg Oncol 1998; 5:670-2.
121. 121 Rubio IT, Korourian S, Cowan C, et al. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol 1998;5:689-94.
122. 122 Keshtgar MRS, Kocjan G, Lakhani SR, et al. Imprint cytology in sentinel node biopsy in breast cancer: is it reliable [abstract]? Eur J Nucl Med 1999;26(suppl):S56.
123. 123 Ku N, Cox C, Reintgen D, et al. Role of intraoperative imprint cytology on sentinel nodes in breast cancer [abstract]. Eur J Nucl Med 1999;26(suppl):S56.
124. 124 Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229: 536-41.
125. 125 Dauway EL, Giuliano R, Pendas S, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher echelon nodes in the axilla [abstract]. Eur J Nucl Med 1999;26(suppl):S92.
126. 126 Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer. J Clin Oncol 1999;17:1720-6.
127. 127 Chu KU, Turner RR, Hansen NM, et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 1999;6:756-61.
128. 128 Giuliano AE. Mapping a pathway for axillary staging. A personal perspective on the current status of sentinel lymph node dissection for breast cancer. Arch Surg 1999;134:195-8.
129. 129 Rahusen FD, Diest PJ van, Meijer S. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary dissection? Ann Surg 2000;231:615-16.
130. 130 Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol 1996;148:649-56.
131. 131 Smith PAF, Harlow SP, Krag DN, et al. Submission of lymph node tissue for ancillary studies decreases the accuracy of conventional breast cancer axillary node staging. Mod Pathol 1999;12:781-5.
132. 132 Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54: 2986-90.
133. 133 Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40.
134. 134 Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998;58:4581-4.
135. 135 Trudeau W, Shivers S, Stall A, et al. Detection of metastases in the sentinel lymph nodes of breast cancer patients by mammaglobin and carcinoembryonic antigen RT-PCR [abstract]. Eur J Nucl Med 1999;26(suppl):S55.
136. 136 Bostick PJ, Huynh KT, Sarantou T, et al. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer 1998;79:645-51.
137. 137 Mori M, Mimori K, Ueo H, et al. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription polymerase chain reaction in patients with gastrointestinal or breast carcinoma. J Clin Oncol 1998;16:128-32.
138. 138 Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet 1997; 349:1668-9.
139. 139 Linehan DC, Hill ADK, Akhurst T, et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999;6:450-4.
140. 140 Klimberg VS, Rubio IT, Henry R, et al. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999;229:860-5.
141. 141 Roumen RMH, Geuskens LM, Valkenburg JGH. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol 1999;25:347-51.
142. 142 Cserni G, Boross G, Baltás B. The value of axillary sentinel nodal status in breast cancer. World J Surg 2000;24: 341-4.
143. 143 Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;227:645-53.
144. 144 Veronesi U, Zurrida S, Galimberti V. Consequences of sentinel node in clinical decision making in breast cancer and prospects for future studies. Eur J Surg Oncol 1998;24: 93-5.
145. 145 Feldman SM, Krag DN, McNAlly RK, et al. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 1999;188:248-54.
146. 146 Dixon M. Sentinel node biopsy in breast cancer. A promising technique, but it should not be introduced without proper trials. BMJ 1998;317:295-6.
147. 147 McNeil C. Sentinel node biopsy: studies should bring needed data. J Natl Cancer Inst 1998;90:728-30.
148. 148 Cibull ML. Handling sentinel lymph node biopsy specimens. A work in progress. Arch Pathol Lab Med 1999;123: 620-1.
149. 149 Zhang PJ, Reisner RM, Nangia R, et al. Effectiveness of multiple-level sectioning in detecting axillary nodal micrometastasis in breast cancer. A retrospective study with immunohistochemical analysis. Arch Pathol Lab Med 1998; 122:687-90.
150. 150 Diest PJ van, Peterse HL, Borgstein PJ, et al. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999;26(suppl):S43-9.
151. 151 Cserni G. Sentinel lymph node biopsy-based prediction of further breast cancer metastases in the axilla. Eur J Surg Oncol [In press.]